28 October 2012
The Russian government plans to actively attract the world's largest pharmaceutical manufacturers to the country, through the creation of conditions to carry out clinical trials of their drugs in the country and providing their access to Russian patients, according to local media reports.
Since the beginning of the current year, the number of drugs which was subject of clinical trials in Russia has almost doubled. According to data of Synergy Research Group, a Russian analytics agency in the field of pharmaceutical business, this year 448 clinical trials were approved in Russia, compared to 201 during the same period of last year.
Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.
The attraction of foreign pharma producers also takes place through the design of legislation, obliging foreign drugmakers to conduct clinical trials of their drugs in Russia in order to sell them on the Russian market. As part of these plans, a federal law “About circulation of drugs” was approved, which simplified the access of foreign pharma producers to Russian patients. As a result, the adoption of the law has resulted in an increase of foreign investments in clinical trials in the territory of Russia.
New legislation expected
In the near future, several new bills are expected to be taken with the aim to eliminate bureaucratic obstacles for clinical trials in the country.
At the same time, according to producers, many Russian patients willingly use any opportunity to participate in clinical trials, sometimes considering this as the only way to receive modern medical treatment.
By tradition, the majority of clinical trials for drugs were accounted for by those designed for cancer treatment, followed by endocrine and infectious diseases. In the third quarter of 2012, among the most active foreign manufacturers in terms of clinical studies conducted in Russian were Amgen (seven trials), followed by Sanofi (six trials), Johnson & Johnson subsidiary Janssen (five trials), AstraZeneca (five trials) and GlaxoSmithKline (five).Print
22 February 2018
21 February 2018
21 February 2018
20 February 2018